{"id":"https://openalex.org/W4322774339","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p2-01-02","title":"Abstract P2-01-02: Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2-negative breast cancer and potential eligibility for adjuvant Olaparib","display_name":"Abstract P2-01-02: Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2-negative breast cancer and potential eligibility for adjuvant Olaparib","publication_year":2023,"publication_date":"2023-03-01","ids":{"openalex":"https://openalex.org/W4322774339","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p2-01-02"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs22-p2-01-02","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p2-01-02","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.sabcs22-p2-01-02","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052971671","display_name":"Stefania Morganti","orcid":"https://orcid.org/0000-0001-5284-9944","observed_orcids":["https://orcid.org/0000-0001-5284-9944"]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stefania Morganti","raw_affiliation_strings":["1Dana-Farber Cancer Institute; Harvard Medical School; Broad Institute of MIT and Harvard","Dana-Farber Cancer Institute","Harvard Medical School"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute; Harvard Medical School; Broad Institute of MIT and Harvard","institution_ids":["https://openalex.org/I107606265","https://openalex.org/I136199984","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Dana-Farber Cancer Institute","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Harvard Medical School","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008682981","display_name":"Qingchun Jin","orcid":"https://orcid.org/0000-0001-6388-5123","observed_orcids":["https://orcid.org/0000-0001-6388-5123"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qingchun Jin","raw_affiliation_strings":["2Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030654805","display_name":"Julie Vincuilla","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julie Vincuilla","raw_affiliation_strings":["3Dana-Farber Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Dana-Farber Cancer Institute","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052536778","display_name":"Ryan Buehler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan Buehler","raw_affiliation_strings":["4Dana-Farber Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Dana-Farber Cancer Institute","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sean Ryan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sean Ryan","raw_affiliation_strings":["5DFCI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5DFCI","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Samantha Stokes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samantha Stokes","raw_affiliation_strings":["6Dana-Faber Cancer Institute; Broad Institute of MIT and Harvard","Dana-Faber Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Dana-Faber Cancer Institute; Broad Institute of MIT and Harvard","institution_ids":["https://openalex.org/I107606265","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Dana-Faber Cancer Institute","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019858534","display_name":"Tonia Parker","orcid":"https://orcid.org/0009-0008-2866-7022","observed_orcids":["https://orcid.org/0009-0008-2866-7022"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tonia Parker","raw_affiliation_strings":["7DFCI, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7DFCI, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029062544","display_name":"Elizabeth Ann Mittendorf","orcid":"https://orcid.org/0000-0002-9762-8536","observed_orcids":["https://orcid.org/0000-0002-9762-8536"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth A. Mittendorf","raw_affiliation_strings":["8DANA-FARBER CANCER INSTITUTE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8DANA-FARBER CANCER INSTITUTE","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076310424","display_name":"Tari A. King","orcid":"https://orcid.org/0000-0003-3602-2351","observed_orcids":["https://orcid.org/0000-0003-3602-2351"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tari King","raw_affiliation_strings":["9Division of Breast Surgery, Department of Surgery, Brigham and Women\u2019s Hospital, Breast Oncology Program, Dana-Farber/Brigham and Women\u2019s Cancer Center, Harvard Medical School"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Division of Breast Surgery, Department of Surgery, Brigham and Women\u2019s Hospital, Breast Oncology Program, Dana-Farber/Brigham and Women\u2019s Cancer Center, Harvard Medical School","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984","https://openalex.org/I4210161994"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012303632","display_name":"Anna Catherine Weiss","orcid":"https://orcid.org/0000-0001-5671-959X","observed_orcids":["https://orcid.org/0000-0001-5671-959X"]},"institutions":[{"id":"https://openalex.org/I4210091146","display_name":"Alliance Foundation Trials","ror":"https://ror.org/00fztf021","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210091146"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anna Weiss","raw_affiliation_strings":["10Alliance Foundation Trials"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Alliance Foundation Trials","institution_ids":["https://openalex.org/I4210091146"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039694693","display_name":"Ann H. Partridge","orcid":"https://orcid.org/0000-0002-4722-4824","observed_orcids":["https://orcid.org/0000-0002-4722-4824"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann Partridge","raw_affiliation_strings":["11Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034347640","display_name":"Brittany Bychkovsky","orcid":"https://orcid.org/0000-0001-7969-0603","observed_orcids":["https://orcid.org/0000-0001-7969-0603"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brittany Bychkovsky","raw_affiliation_strings":["12Comprehensive Breast Health Center, Brigham and Women\u2019s Hospital; Breast Oncology Program, Dana-Farber Brigham Cancer Center Division of Cancer Genetics and Prevention; Dana-Farber Cancer Institute; Harvard Medical School","Comprehensive Breast Health Center, Brigham and Women's Hospital","Dana-Farber Cancer Institute","Harvard Medical School"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Comprehensive Breast Health Center, Brigham and Women\u2019s Hospital; Breast Oncology Program, Dana-Farber Brigham Cancer Center Division of Cancer Genetics and Prevention; Dana-Farber Cancer Institute; Harvard Medical School","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210161994"]},{"raw_affiliation_string":"Comprehensive Breast Health Center, Brigham and Women's Hospital","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Dana-Farber Cancer Institute","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Harvard Medical School","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003897511","display_name":"Giuseppe Curigliano","orcid":"https://orcid.org/0000-0003-1781-2518","observed_orcids":["https://orcid.org/0000-0003-1781-2518"]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giuseppe Curigliano","raw_affiliation_strings":["13European Institute of Oncology, Milano, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13European Institute of Oncology, Milano, Italy","institution_ids":["https://openalex.org/I6141010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062515397","display_name":"Nabihah Tayob","orcid":"https://orcid.org/0000-0001-6088-167X","observed_orcids":["https://orcid.org/0000-0001-6088-167X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nabihah Tayob","raw_affiliation_strings":["14Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"14Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022319770","display_name":"NU Lin","orcid":"https://orcid.org/0000-0003-2263-5413","observed_orcids":["https://orcid.org/0000-0003-2263-5413"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nancy U. Lin","raw_affiliation_strings":["15Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"15Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005206482","display_name":"Judy Ellen Garber","orcid":"https://orcid.org/0000-0001-9449-3982","observed_orcids":["https://orcid.org/0000-0001-9449-3982"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Judy Garber","raw_affiliation_strings":["16Breast Oncology Program, Dana-Farber/Brigham and Women\u2019s Cancer Center, Harvard Medical School, Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"16Breast Oncology Program, Dana-Farber/Brigham and Women\u2019s Cancer Center, Harvard Medical School, Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210161994"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara Tolaney","raw_affiliation_strings":["17Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"17Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003348942","display_name":"Filipa C. Lynce","orcid":"https://orcid.org/0000-0001-6615-7076","observed_orcids":["https://orcid.org/0000-0001-6615-7076"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Filipa Lynce","raw_affiliation_strings":["18Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"18Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"83","issue":"5_Supplement","first_page":"P2","last_page":"01"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.019999999552965164,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.9330000281333923},{"id":"https://openalex.org/keywords/early-breast-cancer","display_name":"early breast cancer","score":0.8700000047683716},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.8169999718666077},{"id":"https://openalex.org/keywords/clinicopathological-features","display_name":"clinicopathological features","score":0.7639999985694885},{"id":"https://openalex.org/keywords/treatment-patterns","display_name":"treatment patterns","score":0.7699999809265137},{"id":"https://openalex.org/keywords/disease-free-survival","display_name":"disease-free survival","score":0.7110000252723694},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8019999861717224},{"id":"https://openalex.org/keywords/recurrence-score","display_name":"recurrence score","score":0.6169999837875366},{"id":"https://openalex.org/keywords/neoadjuvant-chemotherapy","display_name":"neoadjuvant chemotherapy","score":0.8140000104904175},{"id":"https://openalex.org/keywords/adjuvant-chemotherapy","display_name":"adjuvant chemotherapy","score":0.7210000157356262},{"id":"https://openalex.org/keywords/platinum-based-chemotherapy","display_name":"platinum-based chemotherapy","score":0.4519999921321869},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.6340000033378601},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9120000004768372}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8590742349624634},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6857748031616211},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.628383994102478},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6083638668060303},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5463663935661316},{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.49296045303344727},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4562337398529053},{"id":"https://openalex.org/C2779709957","wikidata":"https://www.wikidata.org/wiki/Q17093208","display_name":"Median follow-up","level":3,"score":0.44767889380455017},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.4463627338409424},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.44094550609588623},{"id":"https://openalex.org/C2780194787","wikidata":"https://www.wikidata.org/wiki/Q4836333","display_name":"BRCA mutation","level":4,"score":0.43457284569740295},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.32799991965293884},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs22-p2-01-02","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p2-01-02","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.sabcs22-p2-01-02","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4394841414","https://openalex.org/W4408610768","https://openalex.org/W7129616687","https://openalex.org/W4396633072","https://openalex.org/W4377157973","https://openalex.org/W4379285550","https://openalex.org/W4411291295","https://openalex.org/W4415552183","https://openalex.org/W7204088122","https://openalex.org/W4411289897"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Approximately":[2],"5-10%":[3],"of":[4,54,82,215,320,521,553,571,598,649,668],"early":[5,654],"breast":[6,657],"cancers":[7],"(eBC)":[8],"occur":[9],"in":[10,45,200,286,300,346,503,581,589],"patients":[11],"(pts)":[12],"carrying":[13],"a":[14,79,212,277,314,548],"germline":[15,650],"BRCA1/2":[16,651],"(gBRCA1/2)":[17],"pathogenic":[18],"(P)":[19],"or":[20,136,143,160,253,265,372,585],"likely":[21,443,455],"P":[22],"(LP)":[23],"variant.":[24],"In":[25,516],"the":[26,60,65,125,347,669],"OlympiA":[27,66,126,543],"trial,":[28],"1-year":[29],"(yr)":[30],"adjuvant":[31,663],"(adj)":[32],"olaparib":[33],"(OLA)":[34],"improved":[35],"both":[36,245],"invasive":[37],"disease-free":[38],"survival":[39,43,319,389],"(iDFS)":[40],"and":[41,91,114,162,188,196,235,247,258,299,335,433,453,465,477,535,596,646,659],"overall":[42,348],"(OS)":[44],"gBRCA":[46,172,555],"carriers":[47,107,177,290,556,652],"with":[48,134,153,178,211,302,350,653],"high-risk":[49,61],"HER2-":[50,181],"eBC.":[51,182],"Whether":[52],"benefit":[53,559,575],"adj":[55,120,140,271,403,526,539,561],"OLA":[56,121,540,578],"might":[57],"extend":[58],"beyond":[59],"population":[62],"defined":[63],"by":[64],"criteria":[67],"remains":[68],"to":[69,103,139,158,355,444,456,542,567,579],"be":[70],"defined.":[71],"Methods:":[72],"Consecutive":[73],"pts":[74,227,243,269,275,301,398,406,480,505,522,533,572],"who":[75,557,573],"underwent":[76],"surgery":[77],"for":[78,119,318,402,479,525,538,662],"first":[80],"diagnosis":[81],"eBC":[83,152,306],"at":[84],"Dana-Farber":[85],"Brigham":[86],"Cancer":[87,674,685],"Center":[88],"between":[89,532],"1/2016":[90],"8/2021":[92],"were":[93,97,116,191,326,399,441,523],"identified.":[94],"Genetic":[95],"data":[96],"retrieved":[98],"from":[99,560,576],"an":[100],"institutional":[101],"dataset":[102],"identify":[104,568],"gBRCA1/2":[105],"P/LP":[106],"tested":[108],"through":[109],"Dana-Farber.":[110],"Clinicopathological":[111,642],"variables,":[112],"treatment":[113,644],"outcomes":[115,597,648],"characterized.":[117],"Eligibility":[118],"was":[122,185,206,284,341,391,475,501,530],"based":[123],"on":[124,208],"study":[127],"criteria,":[128],"as":[129,250,263],"follows:":[130],"triple-negative":[131],"BC":[132],"(TNBC)":[133],"\u2265pT2":[135],"\u2265pN1":[137],"prior":[138,157],"chemotherapy":[141],"(ACT)":[142],"non-pCR":[144,161],"after":[145,166,279],"neo-adj":[146],"CT":[147,580,588],"(NACT);":[148],"hormone":[149],"receptor":[150],"(HR)+":[151],"\u22654":[154],"positive":[155],"nodes":[156],"ACT":[159,233,254],"CPS+EG":[163],"score":[164],"\u22653":[165],"NACT.":[167,280],"Results:":[168],"We":[169],"identified":[170],"188":[171],"(105":[173],"BRCA1,":[174],"83":[175],"BRCA2)":[176],"newly":[179],"diagnosed":[180],"Median":[183],"age":[184],"42.5":[186],"years":[187],"119":[189],"(63%)":[190],"premenopausal.":[192],"Tumor":[193],"stage,":[194],"grade":[195,434],"subtype":[197,374],"are":[198],"reported":[199],"Table":[201,593],"1.":[202],"Recurrence":[203],"Score":[204],"(RS)":[205],"performed":[207,447],"46":[209],"pts,":[210],"median":[213,315],"value":[214],"25":[216],"(2%":[217],"0-10":[218],"RS,":[219,222],"52%":[220],"11-25":[221],"46%":[223],"\u226526":[224],"RS).":[225],"97":[226],"(52%)":[228],"received":[229,244,261,270,458],"NACT,":[230],"55":[231],"(29%)":[232,397],"only":[234],"36":[236],"(19%)":[237],"did":[238],"not":[239,483,496,536],"receive":[240],"CT.":[241],"Most":[242],"anthracyclines":[246],"taxanes,":[248],"either":[249],"NACT":[251,264,459],"(68%)":[252],"(53%).":[255],"19":[256],"(20%)":[257],"8":[259],"(8%)":[260],"platinum":[262],"ACT,":[266],"respectively.":[267],"4":[268,329],"OLA.":[272,404,527,562],"43":[273],"(44%)":[274],"had":[276,409],"pCR":[278,282],"The":[281],"rate":[283],"higher":[285,416,582],"BRCA1":[287],"than":[288,304],"BRCA2":[289],"(52":[291],"vs":[292,308,359,362,376,379,412,421,426,431,438,449,461,469,482,507,600],"25%,":[293],"odds":[294],"ratio":[295,365],"(OR)":[296],"3.27,":[297],"p=0.015)":[298],"TNBC":[303,410],"HR+":[305],"(50":[307],"32%,":[309],"OR":[310],"2.10,":[311],"p=0.101).":[312],"After":[313],"follow":[316],"up":[317],"37":[321],"months,":[322],"16":[323],"iDFS":[324,340,474,492,529],"events":[325,493],"recorded,":[327],"including":[328],"second":[330],"primary":[331],"tumors":[332],"(3":[333],"ovarian":[334],"1":[336],"pancreatic":[337],"cancer).":[338],"3-yr":[339,387,473,499,528],"89%":[342],"(95%":[343,368,383,393,487,511],"CI,":[344,369,384,394,488,512],"84-95)":[345],"cohort,":[349,518],"no":[351],"significant":[352],"difference":[353],"according":[354,541],"BRCA":[356],"status":[357],"(BRCA2":[358],"BRCA1:":[360],"85%":[361],"93%,":[363,380],"hazard":[364],"[HR]":[366],"2.65":[367],"0.92-7.63),":[370],"p=0.071)":[371],"tumor":[373],"(HR+":[375],"TNBC:":[377],"87":[378],"HR":[381,509],"1.72":[382],"0.60-4.94),":[385],"p=0.316).":[386],"relapse-free":[388],"(RFS)":[390],"92%":[392],"87-97).":[395],"54":[396],"potentially":[400,586],"eligible":[401,481,484,497,504,524,534,537],"Eligible":[405],"more":[407,454],"frequently":[408],"(67":[411],"36%,":[413],"p<":[414,451,463,471],"0.001),":[415,452],"stage":[417,423,428,655],"(stage":[418],"I":[419],"9":[420],"55%,":[422],"II":[424],"63":[425],"37%,":[427],"III":[429],"28":[430],"9%),":[432],"3":[435],"disease":[436,584,647],"(85":[437],"69%,":[439],"p=0.045),":[440],"less":[442],"have":[445,457],"ODX":[446],"(2":[448],"34%,":[450],"(83":[460],"39%,":[462],"0.001)":[464],"radiation":[466],"therapy":[467],"(78":[468],"33%,":[470],"0.001).":[472],"87%":[476],"90%":[478],"(HR":[485],"1.36":[486],"0.49-3.74),":[489],"p=0.555).":[490],"10/16":[491],"occurred":[494],"among":[495],"pts.":[498],"RFS":[500],"lower":[502,590],"(87":[506],"94%;":[508],"2.23":[510],"0.72-6.92),":[513],"p=0.165).":[514],"Conclusions:":[515],"our":[517],"approximately":[519],"30%":[520],"similar":[531],"criteria.":[544],"Our":[545],"findings":[546],"raise":[547],"concern":[549],"regarding":[550],"proper":[551],"selection":[552],"all":[554],"may":[558,574],"Further":[563],"research":[564],"is":[565],"needed":[566],"additional":[569],"groups":[570],"adding":[577],"risk":[583,591],"replacing":[587],"settings.":[592],"1:":[594],"Characteristics":[595],"gBRCA1":[599],"gBRCA2":[601],"Citation":[602],"Format:":[603],"Stefania":[604],"Morganti,":[605],"Qingchun":[606],"Jin,":[607],"Julie":[608],"Vincuilla,":[609],"Ryan":[610],"Buehler,":[611],"Sean":[612],"Ryan,":[613],"Samantha":[614],"Stokes,":[615],"Tonia":[616],"Parker,":[617],"Elizabeth":[618],"A.":[619],"Mittendorf,":[620],"Tari":[621],"King,":[622],"Anna":[623],"Weiss,":[624],"Ann":[625],"Partridge,":[626],"Brittany":[627],"Bychkovsky,":[628],"Giuseppe":[629],"Curigliano,":[630],"Nabihah":[631],"Tayob,":[632],"Nancy":[633],"U.":[634],"Lin,":[635],"Judy":[636],"Garber,":[637],"Sara":[638],"Tolaney,":[639],"Filipa":[640],"Lynce.":[641],"characteristics,":[643],"patterns":[645],"HER2-negative":[656],"cancer":[658],"potential":[660],"eligibility":[661],"Olaparib":[664],"[abstract].":[665],"In:":[666],"Proceedings":[667],"2022":[670,676],"San":[671,679],"Antonio":[672],"Breast":[673],"Symposium;":[675],"Dec":[677],"6-10;":[678],"Antonio,":[680],"TX.":[681],"Philadelphia":[682],"(PA):":[683],"AACR;":[684],"Res":[686],"2023;83(5":[687],"Suppl):Abstract":[688],"nr":[689],"P2-01-02.":[690]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2023-03-03T00:00:00"}